BIOMAT Database Logo BIOMAT Database Logo

Magnesium intoxication during 1-alpha-hydroxycholecalciferol treatment. 1976

J A Kanis, and R Smith, and R J Walton, and M Bartlett

UI MeSH Term Description Entries
D007408 Intestinal Absorption Uptake of substances through the lining of the INTESTINES. Absorption, Intestinal
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008274 Magnesium A metallic element that has the atomic symbol Mg, atomic number 12, and atomic weight 24.31. It is important for the activity of many enzymes, especially those involved in OXIDATIVE PHOSPHORYLATION.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006887 Hydroxycholecalciferols Hydroxy analogs of vitamin D 3; (CHOLECALCIFEROL); including CALCIFEDIOL; CALCITRIOL; and 24,25-DIHYDROXYVITAMIN D 3. Hydroxyvitamins D,Hydroxycholecalciferol

Related Publications

J A Kanis, and R Smith, and R J Walton, and M Bartlett
Iatrogenic magnesium intoxication during 1-alpha-hydroxycholecalciferol treatment.
July 1976, British medical journal,
J A Kanis, and R Smith, and R J Walton, and M Bartlett
Calcemic response to magnesium or 1-alpha-hydroxycholecalciferol treatment in intestinal hypomagnesemia.
January 1991, Gastroenterologie clinique et biologique,
J A Kanis, and R Smith, and R J Walton, and M Bartlett
[1 alpha-hydroxycholecalciferol in treatment of renal osteodystrophy].
December 1974, Journal d'urologie et de nephrologie,
J A Kanis, and R Smith, and R J Walton, and M Bartlett
[Treatment of postoperative hypoparathyroidism with 1-alpha-hydroxycholecalciferol].
June 1978, Polskie Archiwum Medycyny Wewnetrznej,
J A Kanis, and R Smith, and R J Walton, and M Bartlett
Treatment of anticonvulsant osteomalacia with 1 alpha hydroxycholecalciferol.
February 1977, British medical journal,
J A Kanis, and R Smith, and R J Walton, and M Bartlett
[Treatment of hypoparathyroidism. Trials of 1 alpha-hydroxycholecalciferol (1 alpha-(OH)D3)].
August 1977, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
J A Kanis, and R Smith, and R J Walton, and M Bartlett
[Synthesis of 1 alpha-hydroxycholecalciferol].
January 1973, Helvetica chimica acta,
J A Kanis, and R Smith, and R J Walton, and M Bartlett
[Treatment of renal bone disease with 1-alpha hydroxycholecalciferol].
July 1976, Harefuah,
J A Kanis, and R Smith, and R J Walton, and M Bartlett
[Long-term treatment of renalosteodystrophy with 1 alpha-hydroxycholecalciferol].
January 1982, Revista clinica espanola,
J A Kanis, and R Smith, and R J Walton, and M Bartlett
The treatment of renal osteodystrophy with 1-alpha-hydroxycholecalciferol.
May 1977, Calcified tissue research,
Copied contents to your clipboard!